- Sort by Popularity (sales)
- Display 45 Products per page
Published: August 1, 2004 | Price: $1,995.00 – $5,990.00
The market for OTC Gastrointestinal products has gone through several significant changes in the past 5 years, most of which have to do with the Rx-to-OTC switches of two types of gastroesophageal reflux disease (GERD) drugs: H2 receptor antagonists and proton pump inhibitors (PPIs). This report on the U.S. market for OTC GI products presents a description of upper gastrointestinal conditions and diseases, the OTC treatments available, and clinical and business trends affecting the market, consumer behavior and attitudes, and...Published: August 1, 2004 | Price: $3,500.00 – $7,000.00
This Kalorama Information report focuses on current and emerging immunomodulators for cancer. The report covers both current and emerging cancer immunomodulators in detail. The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development are profiled. These include bladder, breast, colorectal, head/neck, kidney, lung, ovarian, pancreatic, and prostate cancers, as well as leukemia, lymphoma, melanoma, multiple myeloma, and neuroblastoma. The current market...Published: August 1, 2004 | Price: $995.00 – $1,910.00
Blood banking has been the most dynamic testing segment to adopt molecular diagnostics approaches since their introduction. Screening for HIV, HCV and HBV in donated blood, plasma and organs has largely been done by immunoassay procedures. In conjunction with background screening, this has become a very effective approach toward guaranteeing the safety of the blood/organ supply. However, there is a lag time between infection with these viruses and the production of antibodies against them. In some cases, such as HBV,...Published: August 1, 2004 | Price: $895.00 – $1,790.00
After years of neglect, concerns over pain, how it is assessed and managed on a patient-by-patient basis have captured the attention of health care professionals and the public. There are a variety of issues that have acted to draw this attention, including the high prevalence of pain, continuing evidence that pain is undertreated and a growing awareness of the negative consequences of poor pain management. Infusion pumps were first introduced in the 1960s. These devices ushered in a whole new...Published: July 1, 2004 | Price: $895.00 – $1,790.00
Alternative routes of administration for insulin has been one of the leading drivers of drug delivery industry. Although transdermal and transmucosal systems have shown promise and true oral delivery remains a goal, pulmonary delivery has emerged as the leading area of development. Several major players in the pharmaceutical industry have given their backing to inhaled insulin projects, and product launches are imminent. However, the exact make-up of the market, patient acceptance, and regulatory progress are still not completely clear. This...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...Published: July 1, 2004 | Price: $3,500.00 – $7,000.00
New technologies and alternatives to traditional cosmetic surgery have opened up a huge new market for anti-aging products. Cosmetic facial rejuvenation is no longer the purview of plastic surgeons, but represents a booming cash business for a large number of dermatologist and other practitioners. Botox, dermal fillers, resurfacing modalities, lasers, and other alternatives are creating a dynamic and growing marketplace and finding millions of eager patients. This 400-page report examines the competing technologies, procedures, and options available to physicians, non-physician...Published: June 1, 2004 | Price: $3,500.00 – $7,000.00
In 2003, the market for monoclonal antibodies in the treatment of cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 to the present and forecasts the market to 2008, including Kalorama’s estimates of the competitive market share in 2008 based on the current pipeline and...Published: June 1, 2004 | Price: $1,500.00 – $3,000.00
Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. That is, the complex process of creating biologics, means that traditional definitions of bioequivalence used in the generic drug industry do not (or may not)...Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...Published: May 1, 2004 | Price: $3,500.00 – $7,000.00
Molecular diagnostics are seen as being a major breakthrough in medical science. While the technology itself has broad applications to such areas as agricultural bioterrorism and environmental science, medical and medical research applications have provided the primary focus. As a result, great things have been predicted for the development and use of new therapeutics based on molecular testing approaches. The primary molecular diagnostics approaches are based on two major database sciences (genomics and proteomics) and their relationship to disease and...Published: April 1, 2004 | Price: $3,500.00 – $7,000.00
Changing demographics are spurring dynamic growth in the interventional radiology market. The angioplasty balloon, coronary stent, vascular closure, and other associated equipment markets will experience healthy growth over the next 5 years. Persons over the age of 65 will be a major segment of the population in coming years. Chronic diseases and unhealthy habits such as smoking, lack of exercise, and poor diet are resulting in an epidemic of obesity and concomitant cardiac conditions. These factors and others will drive...Published: April 1, 2004 | Price: $1,995.00 – $3,990.00
The recent terrorism events, in addition to the ease of travel that allows infectious diseases to spread, and technology developments drive the renewed interest in clinical and environmental infectious disease diagnostics. The combined public health and bio-terrorism markets of several bacterial and protozoan diseases are estimated to be nearly $100 million. This report, the final volume of the Diagnostics for Emerging Infectious Disease Threats series, focuses on diagnostic testing for 11 bacterial and protozoal diseases in clinical and environmental testing:...Published: March 1, 2004 | Price: $3,995.00 – $7,990.00
A host of new and old infectious diseases have emerged on the world stage, presenting familiar and novel challenges to public health officials. New strains of once controlled bacteria, new immunocomprimised patient populations, and new bioterror threats have spurred diagnostics companies to develop new tests and kits to meet the demand. Kalorama has assembled the vital data developers and marketers need to understand the competitive and commercial landscape in three volumes: Prion Disease; Viral Disease ; and Baterial & Protozoal...Published: March 1, 2004 | Price: $795.00 – $1,590.00
The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or blocks the ability of cells to divide and multiply. Blood and tissue growth factors have become exciting targets for compounds intended to inhibit or slow the mechanisms involved in their function or growth. This report highlights the research into, and the current and potential key world markets for, products that...Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
Cell and tissue therapies are about to revolutionize the treatment of a number of diseases, including: organ, replacement, cartilage, skin, autoimmune diseases, diabetes, neurodegenerative diseases, cancer and cardiovascular tissue damage. Although cell therapy is not a new phenomenon, what is new is the scope and versatility of research using stem cell and tissue therapeutics, and products based on combinations of cell therapy, gene manipulation, and tissue engineering. The report provides world market projections 2002-2007, discusses market trends and issues including...Published: March 1, 2004 | Price: $2,995.00 – $5,990.00
Cardiovascular disease includes chronic conditions such as hypertension, congestive heart failure and atherosclerosis, as well as such acute conditions as myocardial infarction and cardiac arrest. While cardiovascular disease may be diagnosed at any age, it is most prevalent in later years, particularly among sedentary individuals who are also overweight or obese. With the aging of the "Baby Boom" generation, a generation that has defined the term "couch potato" and has grown up on and maintained a diet of fast-food, the...Published: March 1, 2004 | Price: $3,500.00 – $7,000.00
The dialysis industry enjoys a unique space in healthcare sector. The industry has its feet spread across the two most lucrative segments of the sector viz. medical devices industry (dialysis products and supplies segment) and healthcare services industry (dialysis services segment). Needless to say, the dialysis industry remains a robust, nearly $50 billion global industry that has managed to fuel its growth engine with a modest, but respectable 6% to 7% rise growth rate in the past 5 years. The...Published: February 1, 2004 | Price: $3,000.00 – $6,000.00
Diet Aids are among the most rapidly growing categories of over-the-counter (OTC) products. Between 1998 and 2003, growth was driven by two main factors: changes in laws and lawsuits relating to the industry, and changes in consumer attitudes toward weight loss. Because both of these factors are subject to rapid and unpredictable shifts, the diet aids category remains a highly volatile market. The consumer attitude towards OTC diet aids has shown extreme changes during the last couple of years. While...Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
This report provides the reader with a comprehensive analysis of the domestic and international markets involving pharmaceuticals to treat skin diseases and disorders. This edition of Worldwide Market for Prescription Dermatologic Drugs is the fourth time Kalorama Information has comprehensively studied the dermatology markets. For this latest edition, Kalorama completely re-evaluated the market from the ground up, and in addition to the usual primary interviewing of industry participants, clinicians, and regulators, we also conducted scores of interviews with users of...Published: February 1, 2004 | Price: $3,500.00 – $7,000.00
Immunologic approaches to cancer therapy are not only increasing in reputation and number, but the market for these products is increasingly becoming a reality. Vaccines are in the forefront of this approach to cancer, and the handful of cancer vaccine products currently on the market for bladder, colon, and skin cancer are soon to be joined by many more with indications for more wide-spread forms, including lung, breast, ovarian, prostate, leukemia, and others. This new study from Kalorama discusses the...Published: January 1, 2004 | Price: $3,500.00 – $7,000.00
The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...Published: January 1, 2004 | Price: $2,995.00 – $5,990.00
Type II diabetes is a metabolic disease the increases in incidence and prevalence with age. Type II diabetes (also known as "adult onset diabetes" and "non-insulin dependent diabetes") is a disease of glucose metabolism in which the individual becomes resistant to the glucose produced by the pancreas. As a result, glucose is not properly metabolized and serum glucose levels are increased, resulting in numerous complications vascular, renal, neurological and ophthalmological complications as the patient ages. This volume of the Markets...Published: December 1, 2003 | Price: $1,496.00 – $2,992.00
Severe Acute Respiratory Syndrome (SARS), which was a new and unidentified disease when it first affected people, ripped through Asia and Toronto from late 2002 into the summer of 2003, before being contained for the season. Taiwan with just 346 reported cases performed 10,000 diagnostic tests. Three years after West Nile Virus (WNV) first appeared in the United States in 1999 with just 62 cases and 7 deaths, the U.S. Center for Disease Control reports thousands of cases and 150...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...Published: November 1, 2003 | Price: $2,246.00 – $4,492.00
Rheumatoid arthritis is a progressive disease of the joint structure that may be localized or systemic. It varies significantly in severity, producing symptoms that range from minor aches to severe disability and joint deformity. While rheumatoid arthritis can be diagnosed at any age, for childhood to the later years, it most commonly presents with significant symptoms at about middle age. From that point, the disease can progress quickly, slowly or virtually not at all. With an aging population, the unmet...Published: November 1, 2003 | Price: $1,875.00 – $3,750.00
The process of creating a new drug is lengthy and complex. From discovery to development to market, there are numerous pitfalls. In this report, Kalorama focuses on one of the trickiest yet also most promising areas: the interface between discovery and development known as lead optimization. The pressure is on: get better lead compounds faster and at less cost. The amount of money wasted on leads that fail is excessive. And the attrition rate to get a lead is huge....Published: October 1, 2003 | Price: $1,496.00 – $2,992.00
Diagnostic testing for prion diseases has become more important as countries increase the number of tests to battle the potential public health problem. Academic, government, and industry organizations continue to develop diagnostic testing technologies and policies as preventative measures. The number of prion diagnostic technologies being used and developed for prion diseases primarily reflects the scientific and technical challenges of detecting prion proteins. Growth of prion testing will depend on these technology breakthroughs and the future prevalence of prion disease....Published: October 1, 2003 | Price: $2,625.00 – $5,250.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or, in some cases, blocks the ability of cells to divide and multiply. The nature and mode of action of these substances have made them of great interest in various therapeutic areas for which efficacy and specificity must go hand in hand. This report analyzes the world markets for growth factors,...Published: September 1, 2003 | Price: $6,000.00 – $12,000.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. Kalorama has undertaken a major study to examine each of the three main market segments, in turn: Volume I:...Published: September 1, 2003 | Price: $1,875.00 – $3,750.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. This Kalorama specialty report will focus on the products that are currently on the market for surgical and trauma...Published: August 1, 2003 | Price: $1,496.00 – $2,992.00
The OTC women’s health market encompasses a wide variety of products that have been determined safe and effective as over-the-counter products. The market is driven by several factors including increasing number of baby boomers entering old age, increasing incidences of diseases; product demand; and several others. In response to many inquiries from readers of Kalorama Information’s March 2003 publication Women’s Health: Worldwide Prescription Drug Markets, 3rd Edition, we embarked on a supplemental study that goes beyond the prescription market to...Published: August 1, 2003 | Price: $2,625.00 – $5,250.00
This Kalorama Information report—Men’s Health: The World Market for Current and Emerging Drug Therapies—focuses on treatment segments in which men are affected. These segments include: · Men’s Cancer · Sexual Function · Sexually Transmitted Diseases · Urinary Conditions · Andropause The report covers drugs that are used for the treatment of conditions affecting men, including prostate cancer, impotence, and BPH; and areas where diseases and men’s health are a major concern including HIV, herpes, and urinary incontinence. Revenues for product...Published: August 1, 2003 | Price: $1,875.00 – $3,750.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. This Kalorama specialty report will focus on the products that are currently on the market for wound care for...Published: July 1, 2003 | Price: $2,625.00 – $5,250.00
In today's world of Orthopedic Biomaterials, one thing that is expanding rapidly is the amount of new products in the research pipeline: stem cells, bone growth factors, gene therapy, synthetic bone fillers, bioactive implant coatings and biopolymers among others. The overall market is expected to enjoy healthy growth over the next 5 years, but the number one expansion story is in the bone growth factors and proteins segment, so called orthobiologics. These products could grow from just a few percent...Published: July 18, 2003 | Price: $2,625.00 – $5,250.00
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report...Published: June 1, 2003 | Price: $995.00 – $2,992.00
According to the Pharmaceutical Research and Manufacturers of America (PhRMA) more than 1,000 drugs are in various stages of development. Similarly, breakthroughs in the medical device arena such as coronary stents, implantable defibrillators, and minimally invasive bypass surgery and advances in DNA-based tests and other advanced diagnostics are detecting cancer and other diseases earlier when they are more treatable are moving from dream to reality. It is obvious that even if all of these drugs and devices make it to...Published: June 1, 2003 | Price: $1,875.00 – $3,750.00
Wound care has come into its own in the last five years and is now recognized as a specialty. The field has become so diverse and dynamic that studying “the wound care market” as a whole is no longer instructive. As technologies begin to be commercialized and products hit the market, segmentation by application is the key to understanding market potential. This Kalorama specialty report will focus on the products that are currently on the market for wound care for...Published: May 1, 2003 | Price: $2,625.00 – $5,250.00
Genetic testing is already in widespread use and will continue to grow in many application areas in the next five years. The number of companies offering genetic testing services and/or commercial genetic testing products continues to grow around the world. There are at least 50 companies offering genetic testing services or commercial products for a genetic test in medical, GMO food safety, forensics, and paternity applications. In the area of medical genetics, tests and services can vary by disease. Under...Published: May 1, 2003 | Price: $2,625.00 – $5,250.00
Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate. Going OTC is one of a number of strategies marketers can use to extend the revenue life of their products. Appropriately coordinating the switch with patent expiry, creating coherent branding strategies, and knowing the clinical consumer climate are all factors in...Published: May 1, 2003 | Price: $2,062.00 – $4,152.00
The number and scope of drug discovery outsourcing agreements has grown rapidly over the past five years, and the pace will accelerate over the next five years. Outsourcing is now an essential part of drug discovery. Major pharmas and biotechs are aggressively pursuing a range of outsourcing agreements. On the supplier side, smaller vendors rely on outsourcing revenues to pay their bills and boost their credibility. Outsourcing in drug discovery is a popular topic for trade articles and seminars. These...Published: April 1, 2003 | Price: $371.00 – $742.00
The market for diabetes care products covers the spectrum of clinical medicine, including diagnostics, biologics, and drugs. Several areas have strong growth potential and others, such as drugs to treat complications, represent large underserved markets for drugs primarily marketed to other populations. Segmentation of patient populations in novel ways, such as diabetic candidates for cardiovascular drugs, presents an excellent opportunity to expand markets and influence prescription practices in some markets. Scope and Methodology In addition to epidemiology of diabetes Type...Published: April 1, 2003 | Price: $371.00 – $742.00
The market for diabetes care products covers the spectrum of clinical medicine, including diagnostics, biologics, and drugs. Several areas have strong growth potential and others, such as drugs to treat complications, represent large underserved markets for drugs primarily marketed to other populations. Segmentation of patient populations in novel ways, such as diabetic candidates for cardiovascular drugs, presents an excellent opportunity to expand markets and influence prescription practices in some markets. Scope and Methodology In addition to epidemiology of diabetes Type...Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...